QGEN
Price
$47.77
Change
-$0.52 (-1.08%)
Updated
Jul 15, 12:28 PM (EDT)
Capitalization
9.52B
21 days until earnings call
SNN
Price
$29.43
Change
-$0.62 (-2.06%)
Updated
Jul 15, 01:56 PM (EDT)
Capitalization
10.95B
21 days until earnings call
Interact to see
Advertisement

QGEN vs SNN

Header iconQGEN vs SNN Comparison
Open Charts QGEN vs SNNBanner chart's image
Qiagen
Price$47.77
Change-$0.52 (-1.08%)
Volume$2.18K
Capitalization9.52B
Smith & Nephew
Price$29.43
Change-$0.62 (-2.06%)
Volume$522
Capitalization10.95B
QGEN vs SNN Comparison Chart in %
Loading...
QGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
QGEN vs. SNN commentary
Jul 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is QGEN is a StrongBuy and SNN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 15, 2025
Stock price -- (QGEN: $48.28 vs. SNN: $30.04)
Brand notoriety: QGEN and SNN are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: QGEN: 104% vs. SNN: 74%
Market capitalization -- QGEN: $9.52B vs. SNN: $10.95B
QGEN [@Medical Specialties] is valued at $9.52B. SNN’s [@Medical Specialties] market capitalization is $10.95B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.6B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

QGEN’s FA Score shows that 1 FA rating(s) are green whileSNN’s FA Score has 1 green FA rating(s).

  • QGEN’s FA Score: 1 green, 4 red.
  • SNN’s FA Score: 1 green, 4 red.
According to our system of comparison, both QGEN and SNN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

QGEN’s TA Score shows that 2 TA indicator(s) are bullish while SNN’s TA Score has 2 bullish TA indicator(s).

  • QGEN’s TA Score: 2 bullish, 5 bearish.
  • SNN’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, QGEN is a better buy in the short-term than SNN.

Price Growth

QGEN (@Medical Specialties) experienced а +1.58% price change this week, while SNN (@Medical Specialties) price change was +0.33% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -0.18%. For the same industry, the average monthly price growth was +2.33%, and the average quarterly price growth was -1.07%.

Reported Earning Dates

QGEN is expected to report earnings on Nov 04, 2025.

SNN is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Medical Specialties (-0.18% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNN($10.9B) has a higher market cap than QGEN($9.52B). SNN has higher P/E ratio than QGEN: SNN (40.76) vs QGEN (27.85). SNN YTD gains are higher at: 24.233 vs. QGEN (12.132). SNN has higher annual earnings (EBITDA): 956M vs. QGEN (689M). QGEN has more cash in the bank: 1.06B vs. SNN (302M). QGEN has less debt than SNN: QGEN (1.53B) vs SNN (3.08B). SNN has higher revenues than QGEN: SNN (5.55B) vs QGEN (1.97B).
QGENSNNQGEN / SNN
Capitalization9.52B10.9B87%
EBITDA689M956M72%
Gain YTD12.13224.23350%
P/E Ratio27.8540.7668%
Revenue1.97B5.55B35%
Total Cash1.06B302M350%
Total Debt1.53B3.08B50%
FUNDAMENTALS RATINGS
QGEN vs SNN: Fundamental Ratings
QGEN
SNN
OUTLOOK RATING
1..100
2575
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
5
Undervalued
PROFIT vs RISK RATING
1..100
69100
SMR RATING
1..100
8794
PRICE GROWTH RATING
1..100
4847
P/E GROWTH RATING
1..100
285
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SNN's Valuation (5) in the Medical Specialties industry is significantly better than the same rating for QGEN (78). This means that SNN’s stock grew significantly faster than QGEN’s over the last 12 months.

QGEN's Profit vs Risk Rating (69) in the Medical Specialties industry is in the same range as SNN (100). This means that QGEN’s stock grew similarly to SNN’s over the last 12 months.

QGEN's SMR Rating (87) in the Medical Specialties industry is in the same range as SNN (94). This means that QGEN’s stock grew similarly to SNN’s over the last 12 months.

SNN's Price Growth Rating (47) in the Medical Specialties industry is in the same range as QGEN (48). This means that SNN’s stock grew similarly to QGEN’s over the last 12 months.

QGEN's P/E Growth Rating (2) in the Medical Specialties industry is significantly better than the same rating for SNN (85). This means that QGEN’s stock grew significantly faster than SNN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
QGENSNN
RSI
ODDS (%)
Bearish Trend 2 days ago
36%
Bearish Trend 5 days ago
50%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
52%
Bearish Trend 2 days ago
63%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
64%
MACD
ODDS (%)
Bearish Trend 2 days ago
62%
Bearish Trend 2 days ago
61%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
56%
Bullish Trend 2 days ago
53%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
53%
Bearish Trend 2 days ago
64%
Advances
ODDS (%)
Bullish Trend 7 days ago
57%
Bullish Trend 6 days ago
53%
Declines
ODDS (%)
Bearish Trend 9 days ago
51%
Bearish Trend 2 days ago
60%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
51%
Bearish Trend 7 days ago
58%
Aroon
ODDS (%)
Bullish Trend 2 days ago
50%
Bullish Trend 2 days ago
54%
View a ticker or compare two or three
Interact to see
Advertisement
QGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WSHCX63.400.16
+0.25%
American Funds Washington Mutual C
IIIIX12.98N/A
N/A
Voya International Index Port I
AAAAX12.24N/A
N/A
DWS RREEF Real Assets A
JEVIX9.73N/A
N/A
JHancock Disciplined Value Em Mkts Eq I
LICOX17.54N/A
N/A
Lord Abbett International Equity F3